{"ATC Code":"N05BA01","Abbreviation":"Valium","Aliases":["Ansiolisina","Alboral","Methyldiazepinone","Ansiolin","Apozepam","Atensine","Bensedin","Bialzepam","Calmocitene","Calmpose"],"Biological Half-Life":"Diazepam has a biphasic half-life with an initial rapid distribution phase followed by a prolonged terminal elimination phase of 1 or 2 days; its action is further prolonged by the even longer half-life of 2-5 days of its principal active metabolite, desmethyldiazepam (nordiazepam), the relative proportion of which increases in the body on long-term administration. The plasma half-life of diazepam is prolonged in neonates, in the elderly, and in patients with kidney or liver disease.","CAS":"439-14-5","ChEBI":"CHEBI:49575","ChEMBL":"CHEMBL12","ChemicalClasses":["benzodiazepine"],"Chirality":"achiral","Classes":null,"Color/Form":"Colorless to light yellow crysytals","DEA no":2765,"Decomposition":"When heated to decomp it emits very toxic fumes of hydrogen chloride and NO(x)","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"In general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression.  Moreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens.  Furthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare \"stiff man syndrome\".  Particular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery.  In the same UK label information, diazepam is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication.  A diazepam nasal spray is indicated in patients 6 years and older to treat intermittent, stereotypic episodes of frequent seizure activity that are different than the patient's usual seizure pattern.","Drug Warnings":"Since Valium has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium therapy","DrugClasses":["depressant"],"DurationOfAction":"","EINECS":"207-122-5","EliminationHalfLife":"(50 hours); 20–100 hours (32–200 hours for main active metabolite desmethyldiazepam)\u003ca href='#cite_note-5'\u003e\u003csup\u003e[5]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[{"Id":"102355","Title":"Not Noticing Anything From It"},{"Id":"108095","Title":"What's the Big Deal"},{"Id":"115648","Title":"Very Sedative"},{"Id":"12119","Title":"Slow Motion"},{"Id":"21605","Title":"Extremely Relaxed"},{"Id":"23674","Title":"4000mg In Under A Month"},{"Id":"29782","Title":"The Slippery Slope..."},{"Id":"32892","Title":"Flyin' on a Magic Carpet"},{"Id":"43901","Title":"Good High at the Wrong Time"},{"Id":"47971","Title":"Valuims Strange"},{"Id":"48810","Title":"Relaxation, Slight Dizziness"},{"Id":"50400","Title":"Mild but Pleasant"},{"Id":"60572","Title":"Lose Dose Nausea"},{"Id":"60920","Title":"Distance Between Reality and Myself"},{"Id":"6295","Title":"Some Words on After-Effects"},{"Id":"63675","Title":"Vaginal Insertion"},{"Id":"66183","Title":"Total Blackout"},{"Id":"66283","Title":"Like Sailing away...Minus the Costly Yacht"},{"Id":"69057","Title":"I Really Liked It"},{"Id":"79507","Title":"Mellow Yellow Fellow"},{"Id":"80923","Title":"Anxiety Buster, but Not Used to Get 'High'"},{"Id":"92892","Title":"Everything I Wished Drunkenness Would Be"},{"Id":"97526","Title":"So Hard to Sleep"}],"European Community (EC) Number":"207-122-5","FDA Pharmacological Classification":"Q3JTX2Q7TU","FullSalts":["Diazepam hydrochloride"],"HMDB ID":"HMDB0014967","HeavyAtomCount":20,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one","Impurities":["3-amino-6-chloro-1-methyl-4-phenylcarbostyril","1-methyl-4-phenyl-6-chloro-2-quinazolinone","n-(2-benzoyl-4-chlorophenyl)-2-chloro-n-methylacetamide","nordazepam","5-chloro-2-methylaminobenzophenone","7-chloro-2-methoxy-5-phenyl-3h-1,4-benzodiazepine"],"InChI":"InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3","InChIKey":"AAOVKJBEBIDNHE-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)","Melting Point":"257 to 259 °F (NTP, 1992)","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e13\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO","MolecularWeight":"284.74 g/mol","Odor":"Practically no odor","Pharmacodynamics":"Diazepam is a benzodiazepine that exerts anxiolytic, sedative, muscle- relaxant, anticonvulsant and amnestic effects. Most of these effects are thought to result from facilitation of the action of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system.","Physical Description":"Diazepam is an off-white to yellow crystalline powder. Practically odorless. Tasteless at first with a bitter aftertaste. (NTP, 1992)","PrevSalts":["hydrochloride"],"PubChemId":3016,"Record Description":["Diazepam can cause developmental toxicity according to state or federal government labeling requirements.","Diazepam is an off-white to yellow crystalline powder. Practically odorless. Tasteless at first with a bitter aftertaste. (NTP, 1992)","Diazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5. It has a role as a xenobiotic, an environmental contaminant, an anxiolytic drug, an anticonvulsant and a sedative. It is a 1,4-benzodiazepinone and an organochlorine compound.","Diazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589)  Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016. Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential for complete, consistent drug absorption and rapid onset of effect. This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy.","Diazepam is a Benzodiazepine.","Diazepam has been reported in Solanum tuberosum, Glycine max, and other organisms with data available.","Diazepam is a benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","DIAZEPAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA.","Diazepam is a benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589).","A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.","Diazepam can cause developmental toxicity according to state or federal government labeling requirements.","Diazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5. It has a role as a xenobiotic, an environmental contaminant, an anxiolytic drug, an anticonvulsant and a sedative. It is a 1,4-benzodiazepinone and an organochlorine compound.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"RefCount":6,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Diazepam","Name":"Diazepam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q210402","Name":"Diazepam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00829","Name":"Diazepam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3016","Name":"Diazepam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL12","Name":"Diazepam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49575","Name":"Diazepam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=439-14-5","Name":"Diazepam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014967","Name":"Diazepam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C06948","Name":"Diazepam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/Q3JTX2Q7TU","Name":"Diazepam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4020406","Name":"Diazepam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3016, Diazepam. Accessed June 25, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3016\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3016\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Diazepam. UNII: Q3JTX2Q7TU. Global Substance Registration System. Accessed June 25, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q3JTX2Q7TU\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q3JTX2Q7TU\u003c/a\u003e","Valium. January 31, 2020. Accessed June 25, 2025. \u003ca href=https://www.nps.org.au/medicine-finder/valium-tablets#full-pi\u003ehttps://www.nps.org.au/medicine-finder/valium-tablets#full-pi\u003c/a\u003e","Accessed June 25, 2025. \u003ca href=https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/III/paragraph/1\u003ehttps://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/III/paragraph/1\u003c/a\u003e","Diazepam Tablets BP 10 mgs – Summary of Product Characteristics (SmPC). September 16, 2019. Accessed June 25, 2025. \u003ca href=https://www.medicines.org.uk/emc/product/4522/smpc\u003ehttps://www.medicines.org.uk/emc/product/4522/smpc\u003c/a\u003e"],"SMILES":"CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["6JD21U639H"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Brazil","ref":[],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"New Zealand","ref":[],"schedule":"Class C substance"},{"gov":"United Kingdom","ref":["4"],"schedule":"Class C substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"gov":"United Nations","ref":[],"schedule":"schedule IV substance"}],"Solubility":"less than 1 mg/mL at 68 °F (NTP, 1992)","StoreUNII":["Q3JTX2Q7TU"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="95.811mm" version="1.2" viewBox="0 0 84.043 95.811" width="84.043mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="96.0" stroke="none" width="85.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="53.476" x2="55.993" y1=".979" y2="12.023"/>
                  
            <line class="bond" id="mol1bnd2" x1="60.166" x2="71.695" y1="16.608" y2="19.293"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="70.379" x2="77.799" y1="18.986" y2="9.724"/>
                        
                <line x1="72.282" x2="79.702" y1="20.511" y2="11.248"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="77.799" x2="74.089" y1="9.724" y2="14.355"/>
                <line class="hi" stroke="#FF0D0D" x1="79.702" x2="75.99199999999999" y1="11.248" y2="15.8795"/>
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="71.695" x2="78.299" y1="19.293" y2="33.009"/>
                  
            <line class="bond" id="mol1bnd5" x1="78.299" x2="73.482" y1="33.009" y2="43.013"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="56.862" x2="68.391" y1="50.179" y2="47.494"/>
                        
                <line x1="57.464" x2="67.838" y1="47.535" y2="45.119"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="47.494" y2="48.8365"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="45.119" y2="46.327"/>
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="56.862" x2="44.975" y1="50.179" y2="40.629"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.975" x2="44.975" y1="40.629" y2="25.389"/>
                        
                <line x1="42.536" x2="42.536" y1="39.22" y2="26.797"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="53.83" x2="44.975" y1="18.274" y2="25.389"/>
                  
            <line class="bond" id="mol1bnd10" x1="44.975" x2="31.767" y1="25.389" y2="17.769"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="31.767" x2="18.559" y1="17.769" y2="25.389"/>
                        
                <line x1="31.767" x2="20.997" y1="20.584" y2="26.797"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="18.559" x2="18.559" y1="25.389" y2="40.629"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="18.559" x2="31.767" y1="40.629" y2="48.249"/>
                        
                <line x1="20.997" x2="31.767" y1="39.22" y2="45.434"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="44.975" x2="31.767" y1="40.629" y2="48.249"/>
                  
            <line class="bond" id="mol1bnd15" x1="18.559" x2="6.875" y1="40.629" y2="47.377"/>
                  
            <line class="bond" id="mol1bnd16" x1="56.862" x2="53.476" y1="50.179" y2="65.038"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="64.662" x2="53.476" y1="75.402" y2="65.038"/>
                        
                <line x1="61.971" x2="52.851" y1="76.233" y2="67.783"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="64.662" x2="61.276" y1="75.402" y2="90.261"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="46.705" x2="61.276" y1="94.757" y2="90.261"/>
                        
                <line x1="47.331" x2="59.211" y1="92.012" y2="88.346"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="46.705" x2="35.52" y1="94.757" y2="84.393"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="38.906" x2="35.52" y1="69.534" y2="84.393"/>
                        
                <line x1="40.97" x2="38.21" y1="71.449" y2="83.562"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="53.476" x2="38.906" y1="65.038" y2="69.534"/>
                  
            <path class="atom" d="M58.802 18.288h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M83.483 7.396q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM79.62 7.396q-.0 .923 .387 1.458q.392 .53 1.22 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M73.636 49.174h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M2.906 46.435q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .91 .417 1.446q.422 .53 1.268 .53q.321 -.0 .607 -.054q.292 -.059 .565 -.142v.535q-.273 .101 -.565 .149q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.745 .268 -1.31q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.226 -.101 -.506 -.185q-.274 -.083 -.607 -.083zM5.662 50.858h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm14" stroke="none"/>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="55.993" x2="54.7345" y1="12.023" y2="6.5009999999999994"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="60.166" x2="65.9305" y1="16.608" y2="17.950499999999998"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="73.482" x2="75.8905" y1="43.013" y2="38.010999999999996"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="53.83" x2="49.4025" y1="18.274" y2="21.8315"/>
            <line class="hi" id="mol1bnd15" stroke="#1FF01F" x1="6.875" x2="12.717" y1="47.377" y2="44.003"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Adjuvants, Anesthesia; Anesthetics, Intravenous; Anti-Anxiety Agents, Benzodiazepine; Anticonvulsants; Antiemetics; GABA Modulators; Muscle Relaxants, Central; Sedatives, Nonbarbiturate","Title":"Diazepam","UNII":"Q3JTX2Q7TU","Wikidata":"Q210402","Wikipedia":"Diazepam","XLogP":3}